# Kymera (KYMR) Stock Price, News & Analysis
Canonical URL: https://biopharmsignal.com/company/KYMR
## Company Profile
- Ticker: KYMR
- Exchange: NASDAQ
- Sector: Biopharma
- Location: United States
- Tags: PROTACs, Oncology, Immunology
## Stock Data
- Close: 109.62 USD
- Market cap: 5864143448.52 USD
- Last updated: 2026-08-11
## Business Overview
### Targeted Protein Degradation
Kymera Therapeutics develops oral small-molecule degraders that recruit the cell’s protein-disposal machinery to remove disease-causing targets. The platform is intended to address proteins and pathways that are difficult to inhibit with conventional drugs.
### KT-621
KT-621 is a once-daily oral degrader of STAT6, a transcription factor central to IL-4 and IL-13 signaling in type 2 inflammation. Parallel Phase 2b trials are evaluating the candidate in atopic dermatitis and asthma.
### KT-579
KT-579 is an oral degrader of IRF5, a genetically validated regulator of innate and adaptive immune signaling. The candidate is in a first-in-human Phase 1 trial and may have applications across autoimmune diseases including lupus and inflammatory bowel disease.
### Partnered and Emerging Programs
Gilead has licensed KT-200, a CDK2 molecular-glue degrader being prepared for IND-enabling development. Kymera is also advancing additional first-in-class degrader candidates toward clinical entry.
## Why The Stock Is Moving

As of Aug 11, 2026, KYMR closed up 0.96% at $109.62. No new same-company headline was identified in the current news window.

## Future Catalysts

- Phase 1 healthy-volunteer data for KT-579 expected in the second half of 2026.
- Completion of enrollment in the BROADEN2 Phase 2b atopic-dermatitis trial expected in 2026, with data by mid-2027.
- Data from the BREADTH Phase 2b asthma trial expected in late 2027.
- IND filing for Gilead-partnered KT-200 planned in 2027.

## Recent News
- 2026-08-05 11:00 EST — [Kymera Therapeutics Announces Second Quarter 2026 Financial Results and Provides a Business Update](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-announces-second-quarter-2026-financial-results-and-provides-26a4f5e5) — Source: Kymera
- 2026-07-28 20:01 EST — [Kymera Therapeutics to Report Second Quarter 2026 Financial Results on August 5, 2026](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-to-report-second-quarter-2026-financial-results-on-august-5--5364bc95) — Source: Kymera
- 2026-07-27 20:01 EST — [Kymera Therapeutics Appoints Terence Rooney, MD, as Chief Medical Officer](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-appoints-terence-rooney-md-as-chief-medical-officer-93d7b265) — Source: Kymera
- 2026-07-07 11:00 EST — [Kymera Therapeutics Appoints Elizabeth Laws, Ph.D., as Senior Vice President, Global Program Team Leader for KT-621, First-in-Class, Oral STAT6 Degrader](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-appoints-elizabeth-laws-ph-d-as-senior-vice-president-global-f322a3cc) — Source: Kymera
- 2026-06-25 11:00 EST — [Kymera Therapeutics Completes Enrollment in the Phase 2b BROADEN2 Trial of KT-621 in Atopic Dermatitis with Topline Data by Year-end 2026](https://biopharmsignal.com/news/KYMR/kymera-therapeutics-completes-enrollment-in-the-phase-2b-broaden2-trial-of-kt-62-eddcfec5) — Source: Kymera